



Gallagher

Insurance | Risk Management | Consulting

SUMMER 2020

EMI

Employer Market
Intelligence

EMPLOYER MARKET TRENDS

A private ongoing, multiclient study.

Gallagher Research & Insights, St. Louis, MO 63131

© Gallagher Benefit Services, Inc.

All rights reserved. Published 2020

Printed in the United States of America

This Report is licensed only to the original party licensed by Gallagher Benefit Services, Inc. (respectively the "Licensee" and "Gallagher") and is subject to a binding license agreement between Licensee and Gallagher. Gallagher continues to retain title to and ownership of this Report. All copies and portions of this Report, in any form, belong to Gallagher, which retains all rights not expressly granted. Licensee is entitled to use this Report solely for its own internal business purposes and is prohibited from modifying, translating, or otherwise creating derivative works based on this Report. Licensee is further prohibited from licensing, selling, leasing, distributing, lending or otherwise transferring this Report to any third party. Licensee may not make any copies of Gallagher Reports except for internal distribution purposes as described and agreed to in the license agreement provided that all such copies are reproduced with and incorporate all of Gallagher's protective notices, including this and all copyright notices. Nothing in this Report and/or license agreement applicable thereto constitute a waiver of Gallagher's rights under United States Copyright law or any other law.

This information has been obtained from sources which Gallagher believes to be reliable but we do not guarantee the accuracy or completeness of this information.



Gallagher

Insurance | Risk Management | Consulting

SUMMER 2020

EMI

Employer Market
Intelligence

EMPLOYER MARKET TRENDS

A private ongoing, multiclient study.

Table of Contents

| | |
|---|-----------|
| Introduction | 6 |
| Why Employers? | 7 |
| Employer & Coalition Participant Panel | 9 |
| Executive Summary | 11 |
| Employer Segmentation | 18 |
| Segmentation Results | 25 |
| Employer Segmentation Summary | 28 |
| Employer Segmentation—Manufacturer Implications | 29 |
| Pharmacy Benefit Management & Trends | 30 |
| Trends Impacting Pharmacy Benefit Management | 30 |
| Prescription Drug Point-of-Sale Rebates | 34 |
| Pharmacy Purchasing Collectives or Coalitions | 35 |
| Pharmacy Management Initiatives | 37 |
| Reference-Based Pricing for Pharmacy Benefits | 38 |
| Narrow Pharmacy Networks | 38 |
| Value-Based Benefit or Insurance Design (VBBD/VBID) for Pharmacy Benefits | 39 |
| Pharmacy Changes for 2020 | 40 |
| Employer Perspectives on Prescription Drug Formulary & Exclusion Lists | 40 |
| Prescription Drug List (PDL) Approaches | 43 |
| Formulary Exclusions | 47 |
| Alternate Pharmacy Contracting Models | 49 |
| Pharmacy Benefit Management & Trends Summary | 53 |
| Pharmacy Benefit Management & Trends—Manufacturer Implications | 54 |
| Biologics & Biosimilars | 55 |
| Biologics Concerns & Management Initiatives | 55 |
| Copay Accumulator Adjustment Programs | 59 |
| Copay Maximizer Programs | 64 |
| Biosimilars | 65 |
| Employer Biosimilar Knowledge & Perspectives | 66 |
| Biosimilar Benefits Management Approaches | 69 |
| Biologics & Biosimilars Summary | 71 |
| Biologics & Biosimilars—Manufacturer Implications | 72 |

| | |
|---|------------|
| Employee Health Management | 73 |
| Importance of Managing Diseases or Conditions | 73 |
| Conditions Impacting Productivity | 75 |
| Obesity Management | 76 |
| Behavioral Health Services | 77 |
| Employer Worksite Clinics | 78 |
| Value-Focused Health Management Initiatives | 82 |
| Contracting & Payment Terms for Value-Based Services | 84 |
| Consumer-Directed Health Plans (CDHPS) | 88 |
| CDHP Offerings & Enrollment | 88 |
| Health Spending Accounts | 91 |
| Prescription Drug Coverage in a CDHP | 92 |
| Employee Health Management Summary | 95 |
| Employee Health Management—Manufacturer Implications | 96 |
| Employer Health Coalitions | 97 |
| Core Functions of Coalitions & Framework for Collaboration | 97 |
| Quality & Value-Based Initiatives Supported by Coalitions | 100 |
| Disease States or Conditions of Importance to Coalitions | 104 |
| Cancer-Specific Information & Resources | 106 |
| Coalition Member Services | 108 |
| Coalition Data Warehouse | 109 |
| Coalition Pharmacy Group Purchasing | 110 |
| Coalition Group Pharmacy Purchasing: Alternate Rx Contracting | 111 |
| Coalition Involvement in Pharmacy Benefit Design & Management | 112 |
| Coalitions & Copay Accumulator Adjustment Programs (CAAPs) | 113 |
| Coalition Interest in Support & Resources from Manufacturers | 114 |
| Employer Health Coalitions Summary | 117 |
| Employer Health Coalitions—Manufacturer Implications | 118 |
| Appendix | 119 |

List of Figures

| | | |
|-----------|--|----|
| Figure 1 | Overview of Employer Segments | 18 |
| Figure 2 | Distribution of Employers by Quadrant | 25 |
| Figure 3 | Employer Sample by Quadrant | 25 |
| Figure 4 | Segmentation Placement of Research Participants | 26 |
| Figure 5 | Segmentation Placement of Research Participants by Plot Point | 27 |
| Figure 6 | Segmentation Summary | 28 |
| Figure 7 | Importance of Trends Impacting Pharmacy Benefit Management | 30 |
| Figure 8 | Proportion of Employers Increasing Employee Cost Share | 32 |
| Figure 9 | Use of Prescription Drug Point-of-Sale Rebates | 34 |
| Figure 10 | Participation in a Group Rx Purchasing Collective | 36 |
| Figure 11 | Current and Planned Pharmacy Management Initiatives | 37 |
| Figure 12 | Employers with Value-Based Benefit/Insurance Design (VBBD/VBID) for Pharmacy Benefits | 39 |
| Figure 13 | Employer Approach to VBBD/VBID for Pharmacy Benefits | 39 |
| Figure 14 | Employer Perspectives on PBM’s National Formulary and Exclusion Lists | 40 |
| Figure 15 | Degree of Formulary Restriction in Terms of Access & Coverage of Medications | 41 |
| Figure 16 | PBM Contract/RFP Allowances | 42 |
| Figure 17 | Organization’s Approach to the National Prescription Drug List (PDL) | 43 |
| Figure 18 | PBM Action When Employer Modifies Standard Prescription Drug List | 44 |
| Figure 19 | Description of Formulary Modifications | 44 |
| Figure 20 | Degree to Which Employers are Adding and/or Removing Drugs | 45 |
| Figure 21 | Identification of Low-Value vs. High-Value Medications and Services | 46 |
| Figure 22 | 2020 Growth in the Number of Excluded Medications by PBM | 47 |
| Figure 23 | Employers’ Approach to Coverage of Drugs on their PBM’s (or Health Plan’s) Exclusion List | 48 |
| Figure 24 | Description of Alternate Rx Contracting Agreements | 51 |
| Figure 25 | Current and Future Use of Alternate Rx Contracting & Purchasing Models | 52 |
| Figure 26 | Concerns Pertaining to Biologics/Specialty Rx | 56 |
| Figure 27 | Initiatives to Manage Cost & Utilization of Biologics | 57 |
| Figure 28 | Most Effective Employer Initiatives for Managing Cost of Biologics/Specialty Rx | 58 |
| Figure 29 | Disease States for Which Employers Use a Biologics Preferred Drug List | 59 |
| Figure 30 | Utilization of Copay Accumulator Adjustment Program | 60 |
| Figure 31 | Factors Impacting Employers’ Decision to Implement Copay Accumulator Adjustment Programs | 61 |
| Figure 32 | Drug Class for Which Copay Accumulator Adjustment Program is Applied | 61 |
| Figure 33 | Noise or Pushback from Employees about CAAPs | 62 |
| Figure 34 | Impact of CAAPs on Outcomes | 62 |
| Figure 35 | Reasons for Not Implementing Copay Accumulator Adjustment Programs | 63 |
| Figure 36 | Utilization of Copay Maximizer Programs | 64 |
| Figure 37 | Biosimilar Approvals by Originator Manufacturer | 65 |
| Figure 38 | Employer Familiarity with Biosimilars | 66 |

| | | |
|-----------|---|-----|
| Figure 39 | Top Sources for Biosimilar Information and Education, including Cost and Approvals/Pipeline | 66 |
| Figure 40 | Expected Impact of Biosimilars on Total Specialty Drug Spend: 2017-2025 | 67 |
| Figure 41 | Greatest Barriers to Achieving Cost Savings with Biosimilars | 68 |
| Figure 42 | Benefits Management Approaches in Place for Biosimilars | 69 |
| Figure 43 | Medical vs. Pharmacy Benefit Approach to Biosimilar Management | 70 |
| Figure 44 | Importance of Managing Disease States or Conditions to Employers | 74 |
| Figure 45 | Top Disease States or Conditions Impacting Employee Productivity | 75 |
| Figure 46 | Employer Initiatives to Manage Obesity | 76 |
| Figure 47 | Coverage of Newer Weight Loss Medications | 77 |
| Figure 48 | Employer Management of Behavioral Health Services | 77 |
| Figure 49 | Employer Worksite Health Clinics | 78 |
| Figure 50 | Employers Offering Worksite Pharmacies | 79 |
| Figure 51 | Party Responsible for Running Worksite Clinic | 79 |
| Figure 52 | Services Offered at Worksite Clinics | 80 |
| Figure 53 | Disease States/Conditions for Which Services, Initiatives, Education or Other Resources are Offered at Worksite Clinics | 81 |
| Figure 54 | Value-Focused Health Benefit Management. | 82 |
| Figure 55 | Contracting Avenues for Value-Based Initiatives | 84 |
| Figure 56 | Direct-to-Employer Marketing & Contracting for Value-Focused Initiatives | 86 |
| Figure 57 | Use of Risk Sharing (Upside and/or Downside) in Value-Focused Contracts | 87 |
| Figure 58 | Pharmacy Costs Included in Risk Sharing and/or Bundled Payment | 87 |
| Figure 59 | Employers Offering CDHPs | 88 |
| Figure 60 | Employer Approach to CDHP Offerings (2015 to 2020) | 89 |
| Figure 61 | Percentage of Total Covered Lives Enrolled in CDHPs | 90 |
| Figure 62 | Primary Healthcare Account Linked with CDHPs | 91 |
| Figure 63 | CDHP Rx Coverage | 92 |
| Figure 64 | Employers Expanding HSA-Based CDHP Preventive Care Coverage in Light of New IRS Guidelines | 93 |
| Figure 65 | Employer Health Coalitions Leverage their Core Functions to Improve Local/Regional Healthcare | 97 |
| Figure 66 | Guidelines for Coalition Tiers. | 98 |
| Figure 67 | Coalition Targets by Tier. | 99 |
| Figure 68 | Trends Gaining Traction in Coalitions' Local Healthcare Markets in 2020 | 100 |
| Figure 69 | Coalition Provision of Healthcare Quality and Cost Data, Tools and Information to Employer & Community Stakeholders | 102 |
| Figure 70 | Value-Based Initiatives Actively Supported by Coalitions | 103 |
| Figure 71 | Importance of Disease States or Conditions to Coalitions | 105 |
| Figure 72 | Coalition Provision of Cancer-Specific Information & Resources to Employer Members | 106 |
| Figure 73 | Coalition Services Offered to Employer Members | 108 |
| Figure 74 | Coalitions with a Data Warehouse to Collect, Integrate and/or Benchmark Employer Member Benefits Data | 109 |
| Figure 75 | Elements included in Data Warehouse | 109 |

| | | |
|-----------|---|-----|
| Figure 76 | Coalitions Offering Group Pharmacy Benefit Purchasing | 110 |
| Figure 77 | Current and Future Use of Alternate Rx Contracting & Purchasing Models Among Group Purchasing Coalitions | 111 |
| Figure 78 | Coalition Perspectives on Copay Accumulator Adjustment Programs | 113 |
| Figure 79 | Coalition Interest in Receiving Employee Health Management Information and Resources from Manufacturers | 114 |
| Figure 80 | Top Coalition Disease States of Interest for Receiving Information and Support from Manufacturers | 115 |
| Figure 81 | Coalition Interest in Manufacturer Support by Type | 116 |

List of Appendix Figures

| | | |
|-----------|---|-----|
| Figure A1 | Breakdown of Research Participants | 121 |
| Figure A2 | Segmentation Placement of Research Participants by Company Name | 122 |
| Figure A3 | Employers' Health Benefits Insurance Strategies | 123 |
| Figure A4 | Insurance Fee Comparison | 123 |
| Figure A5 | Employer Research Participants | 124 |
| Figure A6 | Coalition Research Participants | 125 |

EMI 2020 Market Overview & Trends Report

Introduction

The 2020 *Employer Market Trends* report is part of the Employer Market Intelligence (EMI) syndicated research service. For sixteen years, this report has tracked and studied the influence of jumbo employer purchasers on access to medications, products and services, and the role they play in driving innovative healthcare solutions.

This primary research was collected via an online survey of benefits decision makers at 103 jumbo employer organizations (5,000+ employees) and leaders of 28 employer health coalitions. Insights were also collected from in-depth interviews with a subset of respondents. Additional details on the research panel can be found on page 9.

While this research was conducted prior to the onset of the COVID-19 pandemic, benefits were established for 2020 and are expected to largely stay in place through the end of the year. Gallagher is tracking employer COVID-19 response efforts and related decision making. Pulse survey results can be found at <https://www.ajg.com/us/coronavirus-covid-19-pandemic/>.

2020 EMPLOYER MARKET TRENDS REPORT TOPICS:

- I. Why Employers?**
- II. Executive Summary**
- III. Employer Segmentation**
- IV. Pharmacy Benefit Management & Trends**
 - » Trends in Pharmacy Benefit Design
 - » Group Rx Purchasing Collectives
 - » VBBD/VBID for Pharmacy Benefits
 - » Formulary & Exclusion List Approach
 - » **NEW!** Degree of Formulary Restriction
 - » **NEW!** PBM Contract/RFP Allowances
 - » **NEW!** Formulary Modifications Applied
 - » **NEW!** Identification of Low-Value vs. High-Value Medications and Services
 - » Alternate Rx Contracting Agreements
- V. Biologics and Biosimilars**
 - » Concerns & Management Initiatives
 - » **NEW!** Most Effective Management Initiatives
 - » Copay Accumulator Adjustment/Maximizer Programs
 - » **NEW!** Barriers to Biosimilar Cost Savings
 - » Biosimilar Benefit Management
- VI. Employee Health Management**
 - » Disease States of Importance
 - » **NEW!** Top Conditions Impacting Productivity
 - » Behavioral Health Management
 - » Worksite Health Clinics
 - » Value-Focused Healthcare Initiatives
 - » **NEW!** Risk Sharing, Bundled Payments and Inclusion of Rx Costs
 - » Consumer-Directed Health Plans
 - » **NEW!** HSA Preventive Coverage Expansion
- VII. Employer Health Coalitions**
 - » Initiatives & Priorities
 - » Coalition Tiering
 - » Group Pharmacy Benefit Purchasing
 - » **NEW!** Cancer-Specific Information Provided to Employers
 - » **NEW!** Interest in Manufacturer Support


Biopharmaceutical manufacturers use this report to better understand the employer market and form a strategic approach to drive change and activation among large employers. Each section provides details and trending data, as well as verbatims that provide a first-hand perspective into employer and coalition viewpoints. A summary and set of implications for biopharmaceutical manufacturers is provided at the conclusion of each section.

Contact Sarah Daley at 314-656-2384 or sarah_daley@ajg.com for questions about this report and the EMI Service, or to set up a presentation of findings.


Employer Participant Panel

103 SURVEYS | 8 INTERVIEWS | 5.8 MILLION COVERED U.S. LIVES

PARTICIPANTS BY NUMBER OF U.S. EMPLOYEES



INDUSTRY




5% Financial Services
 2% Hospitality/Restaurant/Entertainment
 2% Construction
 2% Technology
 1% Energy
 6% Other*

*Other includes: Agriculture; Communications; Media; Public Entity; Religious Institution


EMPLOYER RESPONDENT ORGANIZATIONAL POSITION



GEOGRAPHICAL BREAKDOWN OF EMPLOYER HEADQUARTERS




PERCENT OF ACTIVE EMPLOYEES IN A UNION




Coalition Participant Panel

28 SURVEYS | 3 INTERVIEWS | 20.1 MILLION MEMBER LIVES



COALITION GROUP BENEFIT PURCHASING




COALITION RESPONDENT ORGANIZATIONAL POSITION



SCOPE OF COALITION MEMBERSHIP & ACTIVITY



GEOGRAPHICAL BREAKDOWN OF COALITION LOCATIONS



See Appendix Figures A5 and A6 for a full list of employer and coalition participants.


Employer Segmentation

Gallagher Research & Insights' proprietary segmentation model is a tool that can be used to better understand and predict employer behavior. It allows manufacturers to focus their targeting, engagement and collaboration efforts towards employers who are most likely to take action and have influence in the broader market. In practice, manufacturers utilize the model in a variety of ways, ranging from evaluating the employer market to informing strategy development to targeting employers for engagement through non-personal promotion.

The model emphasizes two central dimensions of employer behavior:

- Willingness to take action to implement solutions (x-axis), and
- Level of strategy in decision making (y-axis).

Figure 1: Overview of Employer Segments



The Most Activated Employers (x-axis)...

- Have independent processes for evaluating vendor partner recommendations
- Are less reliant on benchmarking data, and are among the first to try a new approach
- Have a record of pushing back against recommendations made by vendors (health plan or PBM)

The Most Strategic Employers (y-axis)...

- Have a 3+ year plan for managing health benefits
- Collect and use data from multiple programs (medical, pharmacy, wellness, disability, absence) when planning and evaluating benefit decisions
- Make evidence-based decisions

PHARMACY CHANGES FOR 2020

When employers reflected via a survey write-in response on major pharmacy changes for 2020, responses largely included switching vendors, utilization tactics, more innovative examples of preventive drug list adjustments, formulary customization, participation in group purchasing plans and biosimilar adoption tactics.

“We manage our formulary, so we are consistently adding, removing and writing new PAs for our drug list.”

– Global Health Strategy Manager, Employer

“We created a list of “high value preventive drugs” (i.e., preferred insulin) which we heavily subsidized and added into all medical options (PPO, EPO and HSA-eligible HDHP) to make compliance with chronic condition treatments affordable on a first dollar basis.”

– VP, Health & Wellness, Employer

“We are pushing biosimilar use, with a main barrier of biosimilar coverage residing under the medical plans and not the PBM.”

– Corporate Medical Director, Employer

Segmentation

Rx Benefits


Health Management

Coalitions

Employer Perspectives on Prescription Drug Formulary & Exclusion Lists


Seven in ten employers strongly agree that if presented with compelling evidence, they would be willing to make a formulary change (Figure 14). One-third indicate receiving clinical evidence to support making individualized drug decisions and evaluations, double the proportion just two years ago (see callout). A sizable 44% of employers want to better understand how formulary decisions are made while 39% indicate they trust their PBM’s expertise and rely on their drug coverage recommendations. Just 14% note reluctance to make formularies or exclusion drug list changes due to financial penalties.

Employers increasingly receive clinical evidence to support individual Rx decisions



This year, the percentage of employers willing to make changes and evaluate drug lists rose as did those seeking greater insights around formulary decision making and evidence. Downward trends were recorded only for PBM trust and reluctance to make changes to formularies due to penalties.

Figure 14: Employer Perspectives on PBM’s National Formulary and Exclusion Lists
(percentage strongly agreeing)



Employer Worksite Clinics

Worksite health clinics provide employers the opportunity to broaden and customize readily available healthcare services and contribute to the overall health of employee populations. Additionally, these clinics allow employers to take a hands-on approach when it comes to monitoring and managing both the quality and cost of the healthcare they provide.


On the whole, 43% of surveyed employers currently offer at least one worksite clinic option (onsite and/or near site), and that is expected to increase by fifteen percentage points by 2022 (Figure 49).

Just over one-third of employers (35%) currently offer an onsite health clinic in at least one of their work locations, and nearly half anticipate doing so by 2022. A nearsite clinic model is utilized by 17% of respondents, whereby a clinic is located in close proximity to an employer. The nearsite clinic often provides services to employees in multiple locations at the same organization, or to multiple organizations in the area. By 2022, 29% of employers expect to have a nearsite clinic in place.

Market Drivers Lead Other Segments in Worksite Clinic Offerings

- 49% Offer Onsite Clinic vs. 35% Overall
 - 32% Offer Nearsite Clinic vs. 17% Overall
 - 41% Offer Pharmacies vs. 22% Overall
- See page 18 for Segmentation details.

Figure 49: Employer Worksite Health Clinics



“Take Jackson, Mississippi, where both access and quality of care is low. Even though we don’t have as many employees in that location, we are slated to put a worksite clinic there because they’re our employees and they’re getting poor care. This is more than just a density play. It is about driving change in our local markets.”


– SVP Total Rewards, Employer

Coalition Member Services

Coalitions strive to provide members with services that align with current member priorities, and also anticipate and plan for future needs. Educational and networking conferences are a fundamental service offered by nearly all responding coalitions (Figure 73). Healthcare quality initiatives are offered by 89% of coalitions, up from just 66% of respondents a year ago. This growth underscores the increasing recognition that quality varies and can lead to unnecessary costs and poor health outcomes.

As conveners of employers and other healthcare stakeholders, 75% of coalitions provide valuable benchmarking data, an increase of six percentage points from 2019. This data can be national, regional or both and is often curated via a coalition-owned data warehouse. As member interests shift and different pressure points are addressed or newly manifest, coalition services evolve to meet these changing needs.

Figure 73: Coalition Services Offered to Employer Members



“Creating value and better outcomes is not just one thing. There is a place for a primary care strategy and a worksite clinic strategy as well as a payment reform and value-based insurance design strategy, a Centers of Excellence strategy, etc. We’re trying to keep all of those messages out in front of the employers, and we recognize that the employers all have different populations, different needs. What works in one market or population won’t work in another.”

– President & CEO, Coalition

“The next big focus is going to be specialty drugs, the fastest growing part of the industry. There’s a lot of games being played. We have found a particular PBM consultant that can, predominantly focusing on specialty pharmacies, take the average per member per month pharmacy cost north of \$100 per member per month and reduce that to around \$50 PMPM. We want the middlemen to make a reasonable return. We think the returns they’re making right now are excessive”

– President & CEO, Coalition



Gallagher

Insurance | Risk Management | Consulting

12444 Powerscourt Drive, Suite 250
St. Louis, MO 63131-3612

o 314.968.0011

f 314.968.1199

www.benfieldresearch.com